Buying Alexion remains a “fantastic acquisition” for AstraZeneca, the Big Pharma’s CEO has said, even as the company takes a ...

Despite the discontinuations, CEO Pascal Soriot said AstraZeneca’s December 2020 acquisition of Alexion was a “fantastic” ...

Alexion has routinely featured ... and that was a good call – AstraZeneca has just swooped in with $39 billion cash-and-stock takeover offer. The deal – the largest in the pharma sector ...

AstraZeneca has terminated all development of vemircopan, the oral factor D inhibitor it acquired through the deal for ...

The proposed acquisition will bolster the Alexion, AstraZeneca Rare Disease late-stage pipeline and expand on its bone metabolism franchise with the addition of eneboparatide (AZP-3601), a Phase 3 ...

The European Commission has given competition clearance to the $39 billion acquisition of Alexion by AstraZeneca, leaving the UK as the last remaining obstacle to getting the deal across the line.

The deal brings around $500m of synergies and the technology developed by Alexion complements AstraZeneca’s skills, as it can be applied to more than rare diseases. Meanwhile, Alexion’s ...

AstraZeneca completed the acquisition of Alexion in 2021 and continues to expand its portfolio by bringing innovative therapies for patients living with rare diseases in India. Alexion’s pioneering ...

The turning point that altered the trajectory of its stock price was the company's agreement with Alexion, AstraZeneca Rare Disease for ALXN-1840, signed on October 24, 2024. Monopar shares soared ...